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Antithrombin effect on coagulation and ﬁbrinolytic
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INTRODUCTION
Antithrombin (AT) is a 58-kDa plasma glycoprotein
synthesized in the liver that acts as a serine protease
inhibitor affecting multiple components of the intrin-
sic, extrinsic, and common coagulation pathways
(Quinsey et al., 2004). Palareti et al. (1991) reported
that AT levels are stable during liver transplantation.
In their study, AT levels after surgery were approxi-
mately 80% that of the preoperative level when the
AT concentrate was not administered. During surgery,
Palareti et al. (1991) transfused an average of 8150 ml
fresh frozen plasma, which might have affected AT
levels, because fresh frozen plasma contains high
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SUMMARY
Early after liver transplantation, patients are in a hypercoagulable state
because of an imbalance between coagulation and ﬁbrinolysis because
of the slow recovery of depleted anticoagulant proteins. Antithrombin
(AT) is used in anticoagulant protocols to prevent thrombosis. The
subjects of the present study were 17 men and eight women that
underwent living donor liver transplantation. The initial 15 cases were
administered AT concentrate (1500 U/day) on postoperative days
(POD) 1 through 3 (AT group) and the following 10 consecutive cases
were not administered AT (control). AT, thrombin-AT complex,
plasmin-alpha2 plasmin inhibitor complex, thrombomodulin, ﬁbrin
degradation product D-dimer (FDP-DD) level, prothrombin time
international normalized ratio, activated partial thromboplastin time,
and platelet counts were measured. In the AT group, AT activity was
maintained at levels >80% for 5 days after transplantation. In the
control group, AT activity did not return to normal during the ﬁrst
2 weeks after the operation. FDP-DD levels were signiﬁcantly higher in
the control group than in the AT group (P < 0.05). Six patients in the
control group and three patients in the AT group required transfusions
with platelet concentrate (P < 0.05). AT supplementation might reduce
FDP-DD levels and prevent decreased platelet counts in the early stages
after liver transplantation.
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that the hypercoagulable state persists during the
early period after deceased donor liver transplantation
in cirrhotic patients. There is an imbalance between
coagulation and ﬁbrinolysis because the levels of anti-
coagulant proteins, such as proteins C, S, and AT
return to normal slowly. Hashikura et al.
(1995)advocated that AT should be included in the
anticoagulant protocol during the post-transplant
course for pediatric patients.
A detailed discussion of whether the administration
of AT concentrates is truly necessary after liver trans-
plantation has not yet been presented. The purpose of
this pilot study was to clarify the feasibility of using
AT concentrates in an anticoagulant protocol in the
early stages after liver transplantation.
MATERIALS AND METHODS
The subjects were 17 men and eight women (age
range: 19–67 years; median 51 years) that underwent
living donor liver transplantation at the University of
Tokyo Hospital from July 2005 to April 2006.
Administration of antithrombin concentrates
This pilot study protocol was approved by the Univer-
sity of Tokyo institutional review board. Informed
consent was obtained from all participating patients.
AT concentrates (1500 U/day, Anthrobin P; ZLB Beh-
ring K.K., Tokyo, Japan) were administered to the ini-
tial 15 cases on postoperative days (POD) 1 through 3
(AT group) and no AT was administered in the next
10 consecutive cases (control group).
The indications for living donor liver transplanta-
tion included hepatitis B or C-related cirrhosis (AT
group, n = 9; control, n = 6), cholestatic liver diseases
(AT, n = 4; control, n = 2), fulminant hepatic failure
(AT, n = 1; control, n = 1), alcoholic liver cirrhosis
(control, n = 1), and others (AT, n = 1). The types of
grafts used were right liver (AT group, n = 8; control
group, n = 8), left liver with caudate lobe (AT, n =7 ;
control, n = 1), and right lateral sector (control, n = 1).
Anticoagulant therapy protocol
Except for the AT, both groups were treated with the
same anticoagulant therapy (Kaneko et al., 2005). The
anticoagulant therapy consisted of heparin (unfrac-
tionated heparin sodium, UFH), dalteparin, prosta-
glandin E1, and a protease inhibitor. Initially, we
started dalteparin (25 IU/kg/day) on POD 1, then
switched to UFH (5000 U/day) on POD 2 and 3
because there are fewer hemorrhagic complications in
patients receiving dalteparin than in those receiving
UFH (Dunn & Jarvis, 2000). The dose of UFH was
changed according to the activated clotting time. The
agents were administered by continuous intravenous
infusion. The targeted activated clotting time ranged
between 130 and 160 s. This range corresponded to
the upper half of the normal range of an FTCA510
test tube (normal range 105–167 s) using a HEMO-
CRON Response or Model 401 (International Techno-
dyne Corporation, Lyndhurst, NJ, USA). Prostaglandin
E1 (0.01 lg/kg/h) and a protease inhibitor (mesilate
gabexate; 1 mg/kg/h) were administered intrave-
nously just after the operation for 3 days. When the
platelet count was <30
9/l, patients were transfused
with platelet concentrate. If a patient had more than
one liter of ascites drained, several units of fresh fro-
zen plasma were transfused after liver transplantation.
Monitoring the coagulable and ﬁbrinolytic parameters
Antithrombin (TESTZYM S AT; Daiichi Pure Chemi-
cals, Tokyo, Japan), thrombomodulin (PANACELA
PLATE; DAIICHI Fine Chemical, Toyama, Japan), plas-
min-alpha2 plasmin inhibitor complex (LPIA Ace PPI;
Mitsubishi Kagaku Iatron, Tokyo, Japan), thrombin-
antithrombin complex (SRL, Tokyo, Japan), and ﬁbrin
degradation product D-dimer (FDP-DD, LPIA Ace D-
Dimer; Mitsubishi Kagaku Iatron) were measured the
day before the operation and on POD 1, 2, 3, 5, 7, 10,
and 14. Complete blood count, prothrombin time
international normalized ratio (INR), total bilirubin,
aspartate aminotransferase, alanine aminotransferase,
and creatinine were measured once or twice on
successive days for 2 weeks after living donor liver
transplantation.
Statistical analysis
The time-series coagulable and ﬁbrinolytic data were
compared between the groups by two-way repeated
measures analysis of variance. The number of patients
transfused with platelet concentration and patient
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Student’s t-test. In these analyses, a P-value of <0.05
was considered to be statistically signiﬁcant. Data
from blood samples taken after the operation were
compared with preoperative data in each group by a
multiple comparison using Bonferroni’s correction.
The test was applied for AT, thrombin-antithrombin
complex, PIC, TM, FDP-DD, INR, activated partial
thromboplastin time (APTT), and platelet count, for
which preoperative data were available. A P-value of
<0.0083 was considered to be statistically signiﬁcant. A
statistical analysis software package (SPSS 11.0J, SPSS
Japan Inc., Tokyo, Japan) was used for data analysis.
Data are expressed as mean ± standard deviation.
RESULTS
Patient proﬁles, including age, model for end stage
liver disease score (Wiesner et al., 2003), procured
graft weight, and intraoperative use of fresh frozen
plasma, were not different between groups (Table 1).
Table 1. Patients proﬁles
Groups AT (n = 15)
Control
(n = 10) P-value
Age 52 (23–64) 52 (18–65) 0.96
MELD score 13 (4–37) 18 (7–25) 0.18
Graft weight (g) 529 (348–681) 603 (434–757) 0.07
Fresh frozen
plasma (l)*
3.9 (1.2–5.6) 3.7 (1.2–6.0) 0.7
MELD, model for end-stage liver disease.
*Volume during the operation.
(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
(j) (k)
Figure 1. Changes in the levels of antithrombin (AT, a), thrombin-antithrombin complex (TAT, b), plasmin-alpha2
plasmin inhibitor complex (PIC, c), thrombomodulin (TM, d), ﬁbrin degradation product d-dimer (FDP-DD, e),
prothrombin time international normalized ratio (INR, f), activated partial thromboplastin time (APTT, g), platelet
count (Plt, h), activated clotting time (ACT, i), units of fresh frozen plasma used (FFP, j), and dose of unfractionat-
ed heparin sodium used (UFH, k). Grey bars to the right of the y axis show the normal range. Closed and open
circles are AT and control groups, respectively. The error bars represent standard deviation.
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increased beginning on POD 1 compared with the pre-
operative level and was maintained at >80% until
POD 5. In the control group, AT activity gradually
increased (Figure 1). There was a signiﬁcant difference
between groups (P = 0.03). The thrombin-AT complex
levels were markedly elevated on POD 1 in both
groups and then gradually decreased, although they
did not return to the preoperative level during the
observation period. Thrombin-AT complex levels in
the AT group tended to be higher than those in the
control group, although there was no signiﬁcant dif-
ference between groups (P = 0.06).
The plasmin-alpha2 plasmin inhibitor complex
(P = 0.30) or thrombomodulin (P = 0.88) levels did
not signiﬁcantly differ between groups. The FDP-DD
levels peaked at POD 7 in both groups, but were sig-
niﬁcantly higher in the control group (P = 0.03).
There was no inter-group difference in the INR
(P = 0.40), APTT (P = 0.71), or platelet count
(P = 0.54). Six patients in the control group and three
patients in the AT group were transfused with platelet
concentrate (P < 0.05).
There were no signiﬁcant differences between
groups in the other factors, including activated clot-
ting time (P = 0.71), units of fresh frozen plasma
(P = 0.16), UFH dose (P = 0.09), aspartate amino-
transferase (P = 0.39), alanine aminotransferase
(P = 0.61), total bilirubin (P = 0.34), or creatinine
(P = 0.59). None of the patients experienced compli-
cations such as vascular thrombosis or hemorrhage
during the observation period.
DISCUSSION
Stahl et al. (1990) reported that mean AT activity lev-
els in whole liver transplant recipients are 53% and
67% on POD 3 and 5, respectively. In the control
group in our study, AT activity did not reach normal
levels during the ﬁrst 2 weeks after the operation.
This ﬁnding suggests that the recovery of AT levels
after partial liver transplantation is slower than that
after whole liver transplantation. One possible reason
is that AT is produced by the liver (Bock et al., 1982)
and the level is regulated by the graft size (Kaneko
et al., 2005). Preoperative AT levels (Palareti et al.,
1991) and the time for AT levels to return to normal
after transplantation (Stahl et al., 1990) differ among
the various indications for liver transplantation. The
demographics of Stahl’s patients are similar to those
of ours: 33% and 20% of the patients, respectively,
had cholestatic liver disease.
In pediatric liver transplantation, AT levels during
the postoperative course are seldom reported. Hashik-
ura et al. (1995) suggested that AT levels should
return to 80–100% of preoperative activity 2 weeks
after surgery, based on the antithrombotic effects of
heparin. Indeed, in their study, 2 weeks after surgery,
the administration of AT concentrate increased AT
levels to >80% of its initial activity. In our AT group,
however, AT levels during the ﬁrst 2 weeks after the
transplantation were at least 10% lower than those in
their study. The dose of AT concentrate administered
in the present study was lower than that administered
in Hashikura et al.‘s study to adjust for patient body
weight, although the precise dose was not described
in their report.
Hepatic artery thrombosis is more common in split,
pediatric, or living donor liver transplantation
(Heffron et al., 2005) because of the small diameter of
the anastomosed hepatic arteries. Transplant surgeons
should carefully select the anticoagulant therapy for
partial liver transplantation. An appropriate AT level
for an adequate anticoagulant effect has been
reported. Kauffmann et al. (1978) reported the AT
level threshold with antithrombotic effects in patients
with nephritic syndrome: eight of 11 patients with AT
levels of <70% developed thrombosis, whereas only
one of 37 patients with AT levels >70% experienced
thrombosis. On the other hand, a >60% AT level is
required for heparin to exert an anticoagulant effect
(Francis et al., 1991) to prevent deep vein thrombosis
after orthotopic surgery. In our study, the doses of
UFH and AT might be related. The dose of UFH used
in the AT group tended to be higher than that used in
the control group when activated clotting time was
adjusted to our target level.
It has been controversial whether disseminated
intravascular coagulation (DIC) occurs during
deceased donor liver transplantation. Lewis et al.
(1989) and Bakker et al. (1993) placed doubt on the
existence of DIC during surgery because of the small
decrease in coagulation factors and the lack of an
increase in the levels of ﬁbrin degradation products. A
patient might be in DIC status postoperatively after
liver transplantation. The diagnosis of DIC using a
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post-transplant patients (Carr, McKinney & McDon-
agh, 1989), which makes it difﬁcult to diagnose in this
situation. The high FDP-DD levels and consumption
of concentrated platelets in the control group support
our hypothesis. Low FDP-DD levels and concentrated
platelet consumption indicate that UFH with AT might
be an effective therapeutic combination for DIC.
Ischemia-reperfusion injury in the graft and DIC pres-
ent with a high thrombomodulin level. AT has anti-
inﬂammatory effects on both of these conditions (Sido
et al., 1995; Iba & Kidokoro, 2002), although there
was no signiﬁcant difference in the postoperative
thrombomodulin levels between groups in the present
study.
One of the limitations of this study is that our
anticoagulant protocol is based on activated clotting
time. According to a previous report (De Waele
et al., 2003), activated clotting time is less sensitive
than APTT in low dose UFH (5000–10 000 U/day).
Fluctuation of ACT in this study might also be due
to the other factors than the dose of UFH, including
platelet count and function (Moorehead, Westengard
& Bull, 1984; Girardi, Sudi & Muntean, 2000). The
appropriate target APTT level after liver transplanta-
tion has not been clariﬁed. The ﬁndings of our
study indicate that APTT level was maintained
within the upper half of the normal range during
the ﬁrst week after transplantation. These data
might be helpful for APTT-based anticoagulation
therapy.
CONCLUSION
Antithrombin administration early after partial liver
transplantation might be important for securing an
adequate anticoagulant effect. Although the results of
this pilot study do not prove its clinical advantage, the
combined use of AT and UFH might reduce FDP-DD
levels as well as prevent a postoperative drop in the
platelet count.
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